Integrating Data: Daiichi, Takeda Join Lifestyle Project To Inform R&D
Industry Has Called For Initiatives
Executive Summary
The data collected from wearable devices for a year will provide lifecycle data to a much long-termed study with various health data. The study will not only contribute to drug discovery and personalized healthcare by the firms in near future, but also suggests bigger goals by Japan’s healthcare industry.
You may also be interested in...
Takeda Sees Mainstays Tiding It Over Upcoming Expiries
As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."
Mainstays Give And Take As Major Japan Firms Report Results
While Daiichi Sankyo reveals ambitious plan with Enhertu, Chugai shows stable growth plans with COVID-19 drugs, Astellas reacted to concerns over Xtandi’s slow growth with enthusiastic investment plan for the next potential star.
Arteryex Acquisition To Enhance Eisai's Digital Strategy
Eisai is acquiring Japanese software company Arteryex as part of a digital shift strategy, with the two companies to work together to develop and provide services around personal data, including health records.